CME: The Impact of Abuse-Deterrent Opioids

CME: The Impact of Abuse-Deterrent Opioids
Author Information (click to view)

Marc R. LaRochelle, MD, MPH

Section of General Internal Medicine, Department of Medicine
Boston Medical Center
Assistant Professor of Medicine
Boston University School of Medicine

Marc R. Larochelle, MD, MPH, has indicated to Physician’s Weekly that he has or has had no financial interests to report.

Figure 1 (click to view)
Target Audience (click to view)

This activity is designed to meet the needs of physicians.

Learning Objectives(click to view)

Upon completion of the educational activity, participants should be able to:

 

  • Review a broad history of opioid abuse in the United States.
  • Discuss the findings of a study that assessed the link between the timing of the two opioid market changes—when abuse-deterrent OxyContin was introduced and when propoxyphene was withdrawn—with opioid dispensing and overdose rates from 2003 to 2012.

Method of Participation(click to view)

Statements of credit will be awarded based on the participant reviewing monograph, correctly answer 2 out of 3 questions on the post test, completing and submitting an activity evaluation.  A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.akhcme.com/pwSep04.  You must participate in the entire activity to receive credit.  If you have questions about this CME/CE activity, please contact AKH Inc. at dcotterman@akhcme.com.

Credit Available(click to view)

AKH

CME Credit Provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Physician’s Weekly’s.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

 

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support(click to view)

There is no commercial support for this activity.

Disclosures(click to view)

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use & Investigational Product(click to view)

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer(click to view)

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Faculty & Credentials(click to view)

Keith D’Oria – Editorial Director
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
Marc R. LaRochelle, MD, MPH
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
AKH and PHYSICIAN WEEKLY’S STAFF/REVIEWERS

Dorothy Caputo, MA, BSN, RN- CE Director of Accreditation
Discloses no financial relationships with pharmaceutical or medical product manufacturers.

AKH planners and reviewers have no relevant financial relationships to disclose.

+


Marc R. LaRochelle, MD, MPH (click to view)

Marc R. LaRochelle, MD, MPH

Section of General Internal Medicine, Department of Medicine
Boston Medical Center
Assistant Professor of Medicine
Boston University School of Medicine

Marc R. Larochelle, MD, MPH, has indicated to Physician’s Weekly that he has or has had no financial interests to report.

+
The introduction of abuse-deterrent opioids and the withdrawal of propoxyphene appear to have led to substantial decreases in both prescription opioid dispensing and overdose. Opioid formulation changes may be a viable option toward reducing abuse of these drugs.
Share on FacebookTweet about this on TwitterShare on LinkedIn

According to current estimates, the number of prescription opioid overdose deaths in the United States quadrupled between 1999 and 2010, and this increase occurred in parallel with prescription opioid sales. Studies have also linked the prescription opioid supply to opioid-related overdoses and mortality. As a result, researchers have suggested that it is possible that supply-based interventions may help in the fight against opioid misuse and abuse. However, some have proposed that reducing the prescription opioid supply may lead patients who are already addicted to opioids to substitute illicitly sourced prescription opioids or heroin, an illicit opioid.

 

A History Lesson

OxyContin is an extended-release formulation of oxycodone hydrochloride that is available in higher doses than immediate-release oxycodone. After it was introduced in 1995, it soon became an important drug of choice among people with substance use disorders. “The drug could be chewed and swallowed, or crushed then snorted, or injected to bypass the extended-release mechanism,” explains Marc R. LaRochelle, MD, MPH. “This enabled patients to obtain a quicker and more intense ‘high.’”

Propoxyphene is another agent that has been available for decades to treat pain, but this medication is a considerably weaker opioid analgesic than other agents in the drug class. Despite this knowledge, propoxyphene abuse cases were reported soon after its introduction, and it quickly became a leading agent in prescription drug–induced deaths.

“In late 2010, two important changes occurred in the pharmaceutical market,” says Dr. LaRochelle. “The first was the introduction of abuse-deterrent OxyContin that was resistant to crushing, and the second was withdrawal of propoxyphene, which was found to have cardiac toxicity. By removing opioid formulations associated with increased risk, the hope was that the change would reduce opioid misuse, abuse, and overdose.”

 

Taking a Closer Look

In a study published in JAMA Internal Medicine, Dr. LaRochelle and colleagues assessed the link between the timing of the two opioid market changes—when abuse-deterrent OxyContin was introduced and when propoxyphene was withdrawn—with opioid dispensing and overdose rates from 2003 to 2012. The study group examined claims data on more than 31 million adult members of a national health insurer.

At 2 years after the opioid market changes, fewer prescriptions were dispensed for extended-release oxycodone, propoxyphene, and other immediate-release opioids. Total opioid dispensing decreased by 19% from the expected rate (Figure).

“Overall, the abuse-deterrent formulation of OxyContin resulted in 39% fewer prescriptions for extended-release oxycodone without an increase in alternative extended-release opioid formulations,” says Dr. LaRochelle says. “The sudden drop in dispensing for the abuse-deterrent formulation may have been due to decreased demand from those who were diverting or misusing the older, non-abuse-deterrent formulation.” He adds that there was no suggestion of a shift in formulary or out-of-pocket costs at the time of the formulation change.

In parallel with the decrease in opioid dispensing, the estimated overdose rate attributed to prescription opioids decreased by 20% when assessed at 2 years after the market changes. However, heroin overdose increased by 23% during that same timeframe. Dr. LaRochelle says that further studies are needed to understand the causes of the worsening heroin epidemic and to find ways to better treat patients who use it.

“What is clear from our study is that the introduction of abuse-deterrent OxyContin and the withdrawal of propoxyphene were associated with a decrease in both prescription opioid dispensing and overdoses,” Dr. LaRochelle says. He adds that pharmaceutical market interventions like these may be viable options to help reduce the epidemic of prescription opioid abuse. Opioid formulations that have been linked to high abuse potential or a narrow therapeutic window may represent model targets.

 

Examining the Implications

Results of the study may have significant implications for policymakers and healthcare professionals who are dealing with the opioid epidemic. “Imposing changes with regulatory mandates or voluntary pharmaceutical company actions will not, by itself, solve the drug abuse problem,” Dr. LaRochelle says. “However, it could be part of a multipronged approach to prevent or slow the number of new patients who become addicted to these agents.”

From a policy perspective, it is important to recognize how reducing the opioid supply affects access to these drugs among patients who may possibly benefit from them, says Dr. LaRochelle. “Furthermore,” he says, “prior to recommending abuse-deterrent formulations as first line therapy, we need to determine if they are safer than alternative, potentially less expensive opioids that are not prone to abuse.”

While restricting the opioid supply has the potential to decrease new-onset addiction in the future, Dr. LaRochelle cautions that such actions will not cure existing addiction. “The fact that heroin abuse is becoming more widespread shows that patients are likely to try to find alternatives,” he says. “We need to find ways to better identify and treat patients at risk of opioid abuse as well as heroin while at the same time ensuring that patients have access to the care they need.”

Readings & Resources (click to view)

Larochelle MR, Zhang F, Ross-Degnan D, Wharam F. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med. 2015 Apr 20 [Epub ahead of print]. Available at: http://archinte.jamanetwork.com/article.aspx?articleid=2276923.

Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend. 2014;139:9-17.

Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367:187-189.

Hwang CS, Chang HY, Alexander GC. Impact of abuse-deterrent OxyContin on prescription opioid utilization. Pharmacoepidemiol Drug Saf. 2015;24:197-204.

Jones CM, Paulozzi LJ, Mack KA. Sources of prescription opioid pain relievers by frequency of past-year nonmedical use: United States: 2008-2011. JAMA Intern Med. 2014;174:802-803.

Submit a Comment

Your email address will not be published. Required fields are marked *

20 + 9 =